Voices
Stephen V Liu, SCLC
Stephen V Liu/X

Stephen V Liu: Results from Osimertinib Plus Savolitinib in EGFR NSCLC with MET Amplification After Progression on Osimertinib

Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X about a recent article by Xiuning Le et al. published in Journal of Thoracic Oncology:

“Results from osimertinib plus savolitinib in EGFR NSCLC with MET amplification after progression on osimertinib (cohort in ORCHARD trial) now on Journal of Thoracic Oncology (n=32).

RR 47%, DOR 14.5m, PFS 7.6m, OS 20.7m.”

Title: Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report

Authors: Xiuning Le, Christina Baik, Byoung Chul Cho, Jonathan W. Riess, Zofia Piotrowska, Adrianus Johannes de Langen, Sarah B. Goldberg, Jonathan W. Goldman, Noemi Reguart, Yoshimasa Shiraishi, Helen Ambrose, Paula G. Fraenkel, Brayan Merchan Ruiz, Paul E. Smith, Kwan Ho Tang, Helena A. Yu

Read the Full Article on Journal of Thoracic Oncology

Stephen V Liu: Results from Osimertinib Plus Savolitinib in EGFR NSCLC with MET Amplification After Progression on Osimertinib

More posts featuring Stephen V Liu.

Adrianus Johannes de Langen Brayan Merchan Ruiz Byoung Chul Cho cancer Christina Baik Helen Ambrose Helena A. Yu Jonathan W. Goldman Jonathan W. Riess Kwan Ho Tang Noemi Reguart NSCLC OncoDaily Oncology osimertinib Paul E. Smith Paula G. Fraenkel Sarah B. Goldberg Stephen V Liu Xiuning Le Yoshimasa Shiraishi Zofia Piotrowska